Selected article for: "immune response and obstructive COPD pulmonary disease"

Author: Sainz-Mejías, Maite; Jurado-Martín, Irene; McClean, Siobhán
Title: Understanding Pseudomonas aeruginosa–Host Interactions: The Ongoing Quest for an Efficacious Vaccine
  • Cord-id: t800ifdo
  • Document date: 2020_12_5
  • ID: t800ifdo
    Snippet: Pseudomonas aeruginosa is a leading cause of chronic respiratory infections in people with cystic fibrosis (CF), bronchiectasis or chronic obstructive pulmonary disease (COPD), and acute infections in immunocompromised individuals. The adaptability of this opportunistic pathogen has hampered the development of antimicrobial therapies, and consequently, it remains a major threat to public health. Due to its antimicrobial resistance, vaccines represent an alternative strategy to tackle the pathoge
    Document: Pseudomonas aeruginosa is a leading cause of chronic respiratory infections in people with cystic fibrosis (CF), bronchiectasis or chronic obstructive pulmonary disease (COPD), and acute infections in immunocompromised individuals. The adaptability of this opportunistic pathogen has hampered the development of antimicrobial therapies, and consequently, it remains a major threat to public health. Due to its antimicrobial resistance, vaccines represent an alternative strategy to tackle the pathogen, yet despite over 50 years of research on anti-Pseudomonas vaccines, no vaccine has been licensed. Nevertheless, there have been many advances in this field, including a better understanding of the host immune response and the biology of P. aeruginosa. Multiple antigens and adjuvants have been investigated with varying results. Although the most effective protective response remains to be established, it is clear that a polarised Th2 response is sub-optimal, and a mixed Th1/Th2 or Th1/Th17 response appears beneficial. This comprehensive review collates the current understanding of the complexities of P. aeruginosa-host interactions and its implication in vaccine design, with a view to understanding the current state of Pseudomonal vaccine development and the direction of future efforts. It highlights the importance of the incorporation of appropriate adjuvants to the protective antigen to yield optimal protection.

    Search related documents:
    Co phrase search for related documents
    • action mechanism and acute inflammatory response: 1, 2
    • action mechanism and acute phase: 1, 2, 3, 4
    • action mechanism and acute pneumonia: 1, 2, 3, 4, 5, 6
    • action mechanism and adaptive immune response: 1, 2, 3
    • action mechanism and adaptive response: 1, 2, 3
    • action mechanism and adaptor molecule: 1
    • action mechanism and adenovirus vector: 1
    • action mechanism and adjuvant action: 1
    • action mechanism and adjuvant effect: 1, 2
    • action mechanism and adjuvant system: 1
    • action mechanism and log reduction: 1, 2
    • action mechanism and long term deterioration: 1
    • action mechanism and low molecular weight: 1, 2
    • action mechanism and lps protein: 1, 2
    • action mechanism and lps receptor: 1
    • action mechanism and lps specific: 1
    • action mechanism and lps vaccine: 1
    • action mechanism and lung damage: 1, 2, 3, 4, 5, 6
    • action mechanism and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13